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Background
In sepsis, large scale inflammatory responses can cause extensive collateral damage to 
the vasculature, because both coagulation and fibrinolysis are activated unevenly. 
Thrombin-activatable fibrinolysis inhibitor (TAFI) plays a role in modulating fibrinolysis. 
Since TAFI can be activated by both thrombin and plasmin, it is thought to be affected 
in sepsis. Hence, activated and inactivated TAFI (TAFIa/ai) may be used to monitor changes 
in sepsis.
Methods
TAFIa/ai-specific in-house ELISA can detect only the TAFIa/ai form, because the ELISA cap-
ture agent is potato tuber carboxypeptidase inhibitor (PTCI), which has selective affinity 
towards only the TAFIa and TAFIai isoforms. TAFIa/ai levels in plasma from 25 patients 
with sepsis and 19 healthy volunteers were quantitated with the in-house ELISA.
Results
We observed increased TAFIa/ai levels in samples from patients with sepsis (48.7±9.3
ng/mL) than in samples from healthy individuals (10.5±5.9 ng/mL). In contrast, no differ-
ence in total TAFI concentration was obtained between sepsis patients and healthy 
controls. The results suggest that TAFI zymogen was activated and that TAFIa/ai accumu-
lated in sepsis. 
Conclusion
The detection of TAFIa/ai in plasma could provide a useful and simple diagnostic tool for 
sepsis. Uneven activation of both coagulation and fibrinolysis in sepsis could be caused 
by the activation of TAFI zymogen and elevation of TAFIa/ai. TAFIa/ai could be a novel mark-
er to monitor sepsis and other blood-related disturbances.
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INTRODUCTION
  In sepsis, as a lipopolysaccharide (LPS) is systemically re-
leased, systemic inflammation develops following elevation 
of inflammatory cytokines, including tumor necrosis fac-
tor-alpha (TNFα), interleukin 1 (IL-1), and interleukin 6 
(IL-6), and complement activation [1-4]. Inflammation and 
coagulation are closely interrelated processes, and numerous 
plasma factors such as inflammatory cytokines cause hemo-
static imbalance. IL-lα, IL-lβ, and TNFα promote coagulation 
[5]. In addition, infectious agents directly cause endothelial 
damage, releasing tissue factor (TF) and exposing collagen 
with consequent deregulated coagulation. Both abnormal 
fibrin generation and fibrinolysis have been reported in sepsis 
[6-8]. Disseminated intravascular coagulation (DIC) is a 
well-known fatal complication of sepsis, in which micro-
vascular thrombosis and subsequent multi-organ dysfunction 
commonly lead to the death of patients [6]. 
  Thrombin-activatable fibrinolysis inhibitor (TAFI), a 60- 
kDa glycoprotein zymogen, is the most recently identified 
coagulation factor [9-13]. Upon activation by throm-
bin/thrombomodulin, TAFI becomes the active carbox-
ypeptidase B or U form (TAFIa, 35.8 kDa), and modulates 
fibrinolysis in vivo by cleaving the C-terminal lysine residues 
from partially degraded fibrin [10, 13]. The reduction of 
the C-terminal lysine residues could thereby inhibit the am-
plification of plasminogen activation by tissue plasminogen Korean J Hematol 2010;45:264-8.
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Fig. 1. Thrombin-activatable fibrinolysis inhibitor (TAFI) isoforms in 
plasma. Thrombin/thrombomodulin or plasmin can activate TAFI 
(zymogen, 60 kDa), yielding TAFIa (active form, 35 kDa). Subsequently,
TAFIa is thermally inactivated (triangle) to TAFIai (shaded). All 3 TAFI 
isoforms, TAFI, TAFIa, and TAFIai, are found in plasma. TAFIa/ai-specific
ELISA measured only TAFIa and TAFIai, not TAFI. 
activator (t-PA). On the other hand, plasmin could also acti-
vate TAFI to TAFIa and inactivate TAFI to a 44.3-kDa frag-
ment, depending on the cleavage site [14]. Hence, TAFI 
can be influenced by both coagulation and fibrinolysis, par-
ticularly when hemostasis is interrupted. An interesting char-
acteristic of TAFIa is the rapid irreversible conformational 
change at 37
oC to an inactive isoform called TAFIai (Fig. 
1), which can be measured in plasma [15]. As previously 
reported, potato tuber carboxypeptidase inhibitor (PTCI) se-
lectively binds to both TAFIa and TAFIai, but not TAFI; 
thus, it distinguishes the TAFI isomers in plasma [15]. This 
observation suggests that TAFIai maintains the open active 
site even in its inactive conformation [15]. 
  Various pathological conditions, including tumor, DIC, 
deep venous thrombosis (DVT), and coronary heart disease 
(CHD), give rise to different changes in TAFI levels [16-19]. 
Elevated TAFI levels were observed in DVT and CHD, which 
are thought to be caused by increased levels of coagulation 
factors and consequently increased fibrin clot formation [20, 
21]. DIC is also characterized by increased coagulation 
throughout the body. Reduction of TAFI levels was reported 
in DIC as well as in sepsis, in which a significant depletion 
of TAFI was observed in the presence of pathogens in plasma 
[16]. These results suggest that the consumption of TAFI 
is an important contributing factor in the pathogenesis of 
DIC and sepsis. Moreover, in animal models of sepsis using 
LPS, the supplementation of TAFI was shown to improve 
the disease outcome; this suggested the therapeutic potential 
of TAFI [22]. 
  We hypothesized that in sepsis, the consumption of TAFI 
i n  z y m o g e n  f o r m  w o u l d  r e s u l t  i n  t h e  a c c u m u l a t i o n  o f  
TAFIa/ai in plasma of sepsis patients analyzed using TAFIa/ 
ai-specific ELISA. We found that the TAFIa/ai-specific ELISA 
could be a useful assay to observe the elevation of TAFIa/ai 
in sepsis and could thus be a valuable tool for investigating 
the role of TAFI and its activation pathway in the regulation 
of TAFI-dependent fibrinolytic processes.
MATERIALS AND METHODS
1. Plasma samples
  Citrated plasma samples from 25 sepsis patients (mean 
age, 38.4±21.0 years) and 19 healthy individuals (mean age, 
42.3±12.1 years) were obtained from Soon Chun Hyang 
University or Korea University Hospital with informed con-
sent and under the approval from the institutional review 
board on using the material for this study. Blood was drawn 
from patients with the salient clinical features of systemic 
inflammation (fever, tachycardia, tachypnea and/or hypo-
capnia, and leukopenia or leukocytosis) and a positive culture 
result for pathological microbes. Plasma was processed as 
previously reported by centrifugation at 2,000 g for 15 min 
at 4
oC and subsequent storage at −80°C before use [15]. 
Plasma was taken out of the deep freezer before use and 
thawed on a 37
oC heat block. After 15 min, plasma samples 
were vortexed and then centrifuged for 5 min at 1,500 g. 
Prepared plasma was diluted to 30% with Tris-buffered saline 
with tween-20 (TBST). 
2. Materials
  Purified human TAFI and anti-human TAFI monoclonal 
antibodies were purchased from Hematologic Technologies 
Inc. (Essex Junction, VT, USA). ACTICHROME
Ⓡ TAFI 
Activity kit, D-phenylalanyl-L-prolyl-L-arginine chloromethyl 
ketone (PPACK), thrombin and thrombomodulin were ob-
tained from American Diagnostica Inc. (Stamford, CT, USA). 
Donkey anti-mouse IgG-HRP was obtained from Jackson 
Laboratories (Bar Harbor, ME, USA). TBST, phosphate-buf-
fered saline pH 7.4 (PBS), and PTCI were purchased from 
Sigma Chemical Co. (St. Louis, MO, USA). SuperBlock 
Blocking Buffer, Nunc Maxisorp 96-well black fluorescence 
microtiter plates, sodium carbonate-bicarbonate buffer (pH 
9.4), and ELISA pico-chemiluminescent HRP substrate (ECL 
solution) were from Thermo Scientific (Hudson, NH, USA). 
BlockAce was purchased from Serotec (Kidlington, UK).
3. Preparation of TAFIa and TAFIai
  TAFI was activated by following the reported protocol 
[11], which included incubation with α-thrombin (50 
units/mL), thrombomodulin (3 units/mL), Ca
2+ (5 mM), and 
TAFI (50 μg) in 500 μL of 100 mM TRIS-HCl pH 7.4 for 
20 min at room temperature. PPACK (1 μg) was added to 
prevent TAFI activation by thrombin. TAFIa carbox-
ypeptidase B activity was examined with ACTICHROME
Ⓡ TAFI 
Activity assay. TAFIai was generated by incubation of TAFIa 
at 37
oC for 2 h, completely inactivating the enzymatic activity 
of TAFI.
4. Specific ELISA for TAFIa and TAFIai 
  Specific ELISA for TAFIa and TAFIai (Fig. 2) was devel-
oped previously on the basis of the selective affinity of PTCI 
towards the TAFIa and TAFIai isoforms, and not towards 
the TAFI zymogen form [15]. We measured TAFIa/ai levels Korean J Hematol 2010;45:264-8.
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Table 1. Comparison of activated and inactivated thrombin-activatable
fibrinolysis inhibitor (TAFIa/ai)levels and other coagulation para-
meters between sepsis patients and healthy controls.
Sepsis
N=25
Healthy control
N=19
D-dimer (ng/mL) 2,268±2,393 919±71
FDP (μg/mL) 16.7±17.8 11.3±10.0
PT (sec) 21.5±5.6 13.7±0.1
aPTT (sec) 53.7±22.4 33.3±0.2
Fibrinogen (mg/dL) 376±228 313.1±59
Antithrombin (%) 59.0±30.9 109±16.5
Plt count (×10
3/μL) 159±141 262±55
TAFIa/ai (ng/mL) 48.7±9.3 10.5±5.9
Abbreviations: FDP, Fibrin Degradation Product; PT, prothrombin 
time; aPTT, activated partial thromboplastin time; Plt, platelet.
Fig. 2. Schematic diagram of activated and inactivated thrombin- 
activatable fibrinolysis inhibitor (TAFIa/ai)-specific ELISA. Diluted 
plasma was applied to a potato tuber carboxypeptidase inhibitor 
(PTCI)-coated microtiter plate and incubated for an hour at 37°C.
Following washes, the TAFIa/ai bound to the PTCI-coated plate was 
quantitated with anti-human TAFI antibody and horseradish peroxidase
(HRP)-conjugated anti-mouse IgG antibody.
Fig. 3. Quantitation of activated and inactivated thrombin-activatable 
fibrinolysis inhibitor (TAFIa/ai) levels in plasma from sepsis patients. 
TAFIa/ai levels were quantitated in 25 plasma samples from sepsis 
patients (black circles) and in 19 healthy control plasma samples (white
circles) using TAFIa/ai-specific ELISA. The average values of TAFIa/ai in
sepsis and normal plasma samples were 48.7±9.3 ng/mL and 10.5±
5.9 ng/mL (P＜0.001), respectively. All sepsis patient plasma samples 
showed elevated TAFIa/ai levels.
in patients with sepsis and healthy controls with TAFIai 
by using TAFIa/ai-specific ELISA [15]. Fluorescence micro-
titer plates were coated with PTCI (2 μg/mL) in sodium 
carbonate-bicarbonate buffer and blocked with SuperBlock 
Blocking Buffer or BlockAce. The standard curve was gen-
erated using twofold serial dilution of TAFIa in phosphate 
buffered saline (PBS) containing 0.03% Tween 20. The 
TAFIa, TAFIai, or diluted plasma samples (100 μL) were 
added to the PTCI-coated plate and incubated for an hour 
at 37
oC with gentle shaking. After incubation, the plates 
were washed with TBST 3 times. Anti-human TAFI mono-
clonal antibody was diluted to 1 μg/mL in TBST. Then, 
a 100 μL aliquot of mixed anti-human TAFI monoclonal 
antibody was added to each well and incubated for 1 h 
at 37°C. Later, the plates were washed again with TBST 
3 times. Secondary anti-mouse IgG-HRP (0.1 μg/mL) was 
added in TBST, and a 100 μL aliquot was added to each 
well. After 1-h incubation, plates were washed with TBST 
3 times, and 100 μL aliquot of ECL solution was added to 
each well. The relative light unit (RLU) was measured with 
a PerkinElmer VICTOR3 luminescent microplate reader 
(Waltham, MA, USA). The standard curve was obtained with 
serial doubling dilutions of TAFIai, with concentrations rang-
ing from 75 ng/mL to 2.3 ng/mL. The RLU from each TAFIa/ai 
sample was converted to concentration (ng/mL) using the 
standard curve (not shown).
RESULTS
  Twenty-five sepsis patients meeting the above criteria 
were included in our study. The male:female ratio was 1.2：
1.3, and median age was 38 years (range, 0-88 years). In 
all participants, the blood culture was positive, with 
Escherichia coli being isolated most commonly. Higher levels 
o f  T A F I a / a i  w e r e  d e t e c t e d  i n  p l a s m a  s a m p l e s  f r o m  s e p s i s  
patients than in samples from healthy controls (Table 1). 
The average values of TAFIa/ai in sepsis and normal plasma 
samples were 48.7±9.3 ng/mL and 10.5±5.9 ng/mL (P＜0.001, 
Fig. 3) respectively. All samples from sepsis patients showed 
elevated TAFIa/ai levels than the samples from healthy con-
trols, and the highest value of the healthy samples was 22.7 
ng/mL. Because of the limited number of healthy samples, 
the cut-off value was not set using data from the present 
study, but a larger number of well-characterized samples 
from both sepsis patients and healthy donors would provide 
better assessment of the cut-off values and differentiations. 
When the levels of TAFIa/ai were compared with other 
parameters, such as prothrombin time (PT), activated partial 
thromboplastin time (aPTT), fibrinogen, D-dimer, fibrin deg-
radation product (FDP), antithrombin III, and platelet count, Korean J Hematol 2010;45:264-8.
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no significant correlation was observed (data not shown). 
The coefficient of variation (CV) for both inter- and in-
tra-assays from the TAFIa/ai-specific ELISA was less than 
10%.
DISCUSSION
  Many studies have correlated diseases with measurements 
of the total concentrations of TAFI without segregating the 
following TAFI isomers: TAFI, TAFIa, TAFIai, and 44.3-KDa 
TAFI. A previous study on hemophilia A reported similar 
total concentrations of TAFI in hemophilia A patients and 
healthy controls [23, 24]. On the other hand, the levels 
of TAFI proenzyme were significantly lower in hemophilia 
A patients than in controls. In addition, increased levels 
of TAFIa/ai were reported in hemophilia A patients than 
in healthy individuals. Since thrombin activation is sup-
pressed in hemophilia A patients, these increased TAFI levels 
suggested the involvement of plasmin for minimal activation 
of TAFI in the zymogen form to TAFIa/ai for prevention 
of bleeding. The results of elevated TAFIa/ai levels in sepsis 
patientscoincided with the results from a previous hemo-
philia study [15]. The mean TAFIa/ai antigen levels in hemo-
philia A samples (88.9±49 ng/mL) is higher than those in 
samples from sepsis patients (48.7±9.3 ng/mL). Hence, the 
following hypothesis could be drawn on the basis of the 
results from both hemophilia and sepsis studies. Instead of 
measuring total concentrations of TAFI, the zymogen form, 
or various TAFI isomers, the TAFIa/ai levels could be meas-
ured; this would serve as a simple method for monitoring 
overall changes in TAFI or TAFI activation. Because this 
method is based on the fact that thrombin/thrombomodulin 
or plasmin would convert TAFI to TAFIa, and TAFIa would 
eventually become inactivated to TAFIai, accumulating as 
an end-product in the TAFI activation pathway. In addition, 
since the detection of endogenous TAFIa in plasma is rather 
difficult and TAFIai appears to have a longer half-life than 
TAFIa in plasma, TAFIai could be an easier target to detect 
when diagnosing sepsis or hemophilia.
  Upon infection, many complex processes, such as activa-
tion of the coagulation cascade, neutrophils, proteases, and 
T-cells, degranulation, release of oxygen free radicals, cyto-
kines, and chemokines, and aggregation of platelets, are in-
volved in sepsis leading to endothelial damage [1]. Inflamma-
tion is initiated by cytokines secreted by the phagocytes 
that recognize pathogens. Cytokines cause vasodilatation and 
induction of adhesive molecule expression. Monocytes and 
neutrophils then migrate into the infected tissues. The prog-
ress of sepsis eventually leads to coagulation, in which multi-
ple blood coagulation factors involved in both the activation 
and inactivation of zymogens are simultaneously affected. 
Since TAFI can be activated by both thrombin and plasmin, 
TAFI may be involved in numerous pathological conditions, 
such as tissue inflammation, Budd-Chiari syndrome, hypo-
thyroidism, acute coronary syndrome, rheumatoid arthritis, 
type 2 diabetes, and hemophilia [23-29]. Hence, TAFI could 
be a general, but sensitive, marker for monitoring numerous 
cardiovascular events. 
  Our results also support the proposal to use TAFI as a 
therapeutic drug against sepsis. This proposal was based on 
the findings of studies on sepsis in mouse and baboon models 
[22]. After the administration of LPS, supplementation of 
TAFI prevented the dysfunctional response of vascular endo-
thelial cells, similar to the protective mechanism of activated 
protein C.
  In conclusion, the TAFIa/ai-specific ELISA demonstrated 
higher levels of TAFIa/ai in plasma samples from patients 
with sepsis than in samples from healthy controls. These 
results were consistent with those of our previous hemophilia 
study. The assay was specific for 2 35-kDa activation isoforms 
of TAFI, namely, TAFIa and TAFIai, but not for the TAFI 
zymogen. The presence of elevated levels of TAFIa/ai would 
suggest an up-regulation of the TAFI activation pathway 
and depletion of TAFI zymogen in both hemophilia and 
sepsis. TAFIa/ai, measured by TAFIa/ai ELISA, could be used 
as a novel marker for monitoring perturbation of hemostasis. 
Monitoring TAFIa/ai antigen levels in plasma would serve 
as an ideal method to follow the post-treatment progress 
of recovery from sepsis. 
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